Clinical Trial Search

Primary: Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score — -5.0; -5.2; -8.0; -9.8 units on a scale — p=<0.05

Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) — -2.97; -3.36; -3.33 units on a scale — p=0.008

Primary: Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the First Vaccination — 29; 53; 62; 95 Participants

Primary: Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS). — -0.11; -0.07 Units on a scale

Primary: Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against Each Antigen Included in the 2008-2009…

Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants

Primary: Occurrence of a Clinically Significant Thrombocytopenic Event — 11; 8; 10; 11 Participants

Primary: Number of Patients With Improvement in Liver Histology — 12 participants

Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants

Primary: Patient Response to Treatment — 1; 10; 10; 4 participants

Primary: Percentage of Participants Achieving Pathologic Complete Response (pCR) — 24.3; 25.2 Percentage of Participants — p=0.8921

Primary: Number of Participants Who Developed a Major Depressive Episode According to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During…

Primary: Number of Participants With Objective Clinical Response — 0; 1; 7; 26 Participants

Primary: Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids — 2.22; 3.10; 2.83; 3.05 scores

Primary: Number of Patients Without GVHD at 100 Days — 100 participants